NASDAQ:APRE • US03836J2015
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for APREA THERAPEUTICS INC (APRE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-10 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-01-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-27 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-03-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-10 | Maxim Group | Initiate | Buy |
| 2022-07-08 | Wedbush | Initiate | Outperform |
| 2021-08-20 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2021-08-16 | Berenberg | Downgrade | Buy -> Hold |
| 2021-08-16 | HC Wainwright & Co. | Maintains | Neutral |
| 2021-08-13 | RBC Capital | Maintains | Sector Perform |
| 2021-08-13 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 583.2K | 1.503M 157.65% | 299.543K -80.06% | 102K -65.95% | 1.195M 1,071.57% | 67.805M 5,574.06% | 49.704M -26.70% | 121.31M 144.06% | 186.21M 53.50% | 326.77M 75.48% | 530.18M 62.25% | ||
| EBITDA YoY % growth | -113.39M -202.86% | -15.465M 86.36% | -14.297M 7.55% | -14.586M -2.02% | -16.014M -9.79% | -19.176M -19.75% | -24.684M -28.72% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -113.39M -202.78% | -15.472M 86.36% | -14.32M 7.45% | -14.523M -1.42% | -16.625M -14.48% | -18.916M -13.78% | 26.026M 237.59% | 15.684M -39.74% | 73.714M 369.99% | 148.37M 101.28% | 274.49M 85.00% | 457.16M 66.55% | |
| Operating Margin | N/A | -2,652.95% | -952.99% | -4,848.41% | -16,299.33% | -1,582.95% | 38.38% | 31.55% | 60.76% | 79.68% | 84.00% | 86.23% | |
| EPS YoY % growth | -30.12 13.94% | -3.99 86.75% | -2.38 40.35% | -2.03 14.71% | -1.20 40.87% | -0.86 28.05% | 1.22 241.73% | 0.70 -42.50% | 2.44 246.38% | 4.81 97.49% | N/A | N/A |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.40 18.82% | -0.32 63.58% | -0.14 73.25% | -0.16 65.71% | -0.12 70.26% |
| Revenue Q2Q % growth | -100.00% | -100.00% | N/A | N/A | N/A |
| EBITDA Q2Q % growth | -3.774M -17.80% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.688M -14.33% | -3.511M 14.07% | -3.664M -8.15% | -3.969M -27.31% | -4.122M -11.75% |
All data in USD
9 analysts have analysed APRE and the average price target is 5.44 USD. This implies a price increase of 639.13% is expected in the next year compared to the current price of 0.736.
APREA THERAPEUTICS INC (APRE) will report earnings on 2026-03-23, after the market close.
The consensus EPS estimate for the next earnings of APREA THERAPEUTICS INC (APRE) is -0.4 USD and the consensus revenue estimate is 0 USD.
The consensus rating for APREA THERAPEUTICS INC (APRE) is 84.4444 / 100 . This indicates that analysts generally have a positive outlook on the stock.